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Introduction
Due to the great variability and high glycosylation of
gp120, possible targets for a fusion inhibitor include the
CD4 binding region of gp120. Here we describe a method
by which peptides corresponding to residues 25 to 64 of
the CD4 receptor have been coupled to a major antigen,
the gal-alpha 1,3-gal disaccharide, towards which humans
have natural antibodies. Use of these fusion-molecules
should redirect the specificity of the antibodies towards
gp120 and possibly help reducing the viral loads of
infected individuals.
Materials and methods
Binding of human anti gal-alpha 1,3-gal antibody glyco-
peptide complexes to gp120 and the virus was analysed by
ELISA and a neutralization assay. The latter was based on
reduction of syncytia in U87 cells in the presence of heat
inactivated human serum from healthy individuals. Non-
inactivated serum was also used to analyse the contribu-
tion of the complement dependent cytotoxicity to the sys-
tem.
Results
Binding of the molecules was confirmed both by ELISA
and by neutralization using the HIV 1 IIIB virus at several
concentrations of the peptides with a 1:10 or 1:20 dilu-
tion of the human serum. Furthermore, complement pro-
teins contributed to the neutralization capacity of the
human anti gal-alpha 1,3-gal antibody- glycopeptide
complexes.
Conclusion
Taking advantage of the innate response by redirecting the
specificity of natural antibodies could be a complement to
existing anti retroviral therapy of HIV infected individuals.
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